Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$52 Mln
P/E Ratio
--
P/B Ratio
0.39
Industry P/E
--
Debt to Equity
0.14
ROE
-0.69 %
ROCE
-63.04 %
Div. Yield
0 %
Book Value
1.73
EPS
-1.67
CFO
$-359.12 Mln
EBITDA
$-466.92 Mln
Net Profit
$-439.13 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Prelude Therapeutics Inc (PRLD)
| -29.34 | 25.13 | -25.85 | -76.72 | -44.25 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Prelude Therapeutics Inc (PRLD)
| -69.84 | -29.30 | -51.49 | -82.60 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,135.98 | 20.78 | 23.13 | |
| 298.55 | 8,668.61 | 21.55 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,030.35 | 30.81 | 14.16 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein... for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805 Read more
Founder, CEO & Director
Dr. Krishna Vaddi D.V.M., Ph.D.
Founder, CEO & Director
Dr. Krishna Vaddi D.V.M., Ph.D.
Headquarters
Wilmington, DE
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Prelude Therapeutics Inc (PRLD) stood at $ 176 Mln as on 31-Dec-24
The share price of Prelude Therapeutics Inc (PRLD) is $0.90 (NASDAQ) as of 25-Apr-2025 16:24 EDT. Prelude Therapeutics Inc (PRLD) has given a return of -44.25% in the last 3 years.
Prelude Therapeutics Inc (PRLD) has a market capitalisation of $ 52 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Prelude Therapeutics Inc (PRLD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Prelude Therapeutics Inc (PRLD) and enter the required number of quantities and click on buy to purchase the shares of Prelude Therapeutics Inc (PRLD).
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805
The CEO & director of Dr. Krishna Vaddi D.V.M., Ph.D.. is Prelude Therapeutics Inc (PRLD), and CFO & Sr. VP is Dr. Krishna Vaddi D.V.M., Ph.D..
There is no promoter pledging in Prelude Therapeutics Inc (PRLD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Prelude Therapeutics Inc (PRLD) | Ratios |
|---|---|
|
Return on equity(%)
|
-69.01
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-1816.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Prelude Therapeutics Inc (PRLD) was $0 Mln.
$0.04
(
